Related Experiment Video

Updated: May 25, 2026

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma

Z Wang1, T Zheng, Q Wu

  • 1Department of Oncology, Changzheng Hospital, Second Military Medical university, Shanghai, China.

Neoplasma
|January 18, 2012
PubMed

Insights

Activated mTOR pathway proteins are highly prevalent in intrahepatic cholangiocarcinoma (ICC) tumors. This suggests many ICC patients may benefit from targeted therapies, with p-4EBP1 serving as a potential prognostic biomarker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with limited treatment options.
  • The mammalian target of rapamycin (mTOR) pathway plays a crucial role in cancer cell growth and survival.
  • Targeting the mTOR pathway with inhibitors is a potential therapeutic strategy for various cancers.

Purpose of the Study:

  • To investigate the expression of activated mTOR and its downstream targets, phosphorylated p70 ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1), in ICC.
  • To determine the correlation between mTOR pathway activation and clinicopathological characteristics and prognosis in ICC patients.
  • To evaluate the potential of mTOR pathway inhibitors as a targeted therapy for ICC.

Main Methods:

  • Immunohistochemistry was used to detect activated mTOR (p-mTOR at Ser 2448), p-p70S6K (at Thr 389), and p-4EBP1 (at Thr 70) in 77 primary ICC tumors.
  • Statistical analysis was performed to correlate protein expression levels with clinicopathological features and patient survival.
  • Multivariate analysis was employed to identify independent prognostic factors.

Main Results:

  • High expression levels of activated mTOR, p-p70S6K, and p-4EBP1 were observed in a significant proportion of ICC tumors (48.1%, 51.9%, and 50.6%, respectively).
  • High p-p70S6K expression was associated with poorly differentiated ICC, while high p-4EBP1 expression predicted poor prognosis and was an independent prognostic factor.
  • No significant correlation was found between mTOR pathway protein overexpression and other clinicopathological characteristics.

Conclusions:

  • The mTOR pathway is frequently activated in ICC, indicating that a substantial number of patients could benefit from mTOR-targeted therapies.
  • Phosphorylation of 4EBP1 at Thr 70 may serve as a valuable prognostic biomarker for ICC patients.
  • These findings support further investigation into mTOR inhibitors for ICC treatment.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...